India Pharma 2021

#IndiaPharma2021- An International Exhibition & Conference on #Pharmaceutical Industry is a joint initiative of @pharmadept and @ficci_India.

[FICCI @ficci_india]

FICCI wishes you a #HappyHoli2021!
Celebrate the riot of colors together with a dash of SMS (Sanitizer- Mask- Social Distancing)
#FICCIforSMS #Holi2021

@ushanx @subhrakantpanda @drsangitareddy @rasheshshah

[India Pharma 2021 @Ind_Pharma]

Thank you for being a part of this wonderful journey at #IndiaPharma2021 & #IndiaMedicalDevice2021. As we conclude the ceremonies, we wish you a year of learning & prosperity. Let us together make an #AtmaNirbharBharat. Catch us on our Next Edition.

[India Pharma 2021 @Ind_Pharma]

"Consumers are seeking information. They are seeking access & they are seeking a platform they can trust to get that kind of an access"-Mr. @tandon_Prashant , CEO @1mgOfficial at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"How many people have access to digital technology in this country? We need to evolve as far as patients are concerned – we need to achieve 100% digital penetration"-Mr. Harish Jain at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"Making the right reimbursement decisions can lead to future savings. The same budget can be used somewhere else. This improves the efficiency of the system"-Mr. Subrata Bhattacharyya, Health Economist, Founding Director @PharmaQuant at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"The time has come to look at the OTC medicines & bring about these regulations & improve the healthcare & well-being of people"-Mr. Bala Gopal Nair , Regional Medical Director, Abbott India at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"One of the key questions that we as a country can ponder on & ask is how can we empower the patients to take care of their health using multiple different new technologies & digital tools that are getting created"-
Mr. @pramodsudhindra ,EY at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"The whole idea of having a subject expert committee & they giving the inputs around the whole bit & then the approvals, is a very welcome thing that has happened over the last few years"-Mr. Saumil Mody, Oncology General Manager at @NovartisCancer at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"The volumes of patients for rare diseases in India is quite low. It’s very difficult to have multiple manufacturing locations, whether it is an Indian company or MNC"- Mr. @anilraina1969 , General Manager @SanofiGenzyme at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"We need to acknowledge that when it comes to rare diseases, there is very limited patient population & there isn’t much incentive to invest in R&D, with very few companies in the space"-Mr. V Simpson Emmanuel , MD @Roche at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"The industry has to take care of the fact that most times the low cost of their products is not getting reflected into the benefit of the patients"-Mr. @Professor_gupta ,President AIIMS Bhopal at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"We needed to become patient-centric. We started looking at the needs of the patients instead. What can be done in the interests of the patients through the doctor’s prescription"-Mr. @Satishkreddy, Chairman @drreddys at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"We need to expedite without compromising quality – from the research to development to marketing approach for the system"-Mr. V.K Paul, Member- Health @NITIAayog GOI at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"Regarding privatization, what we are going to be looking at is the development of a personalized healthcare experience that is increasingly becoming necessary"- Ms. S Aparna, Secretary @Pharmadept , Ministry of C&F ,GOI at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"The steps taken by the Government are in the right direction, taking us towards an universal healthcare & providing a better solution for our population"-Mr. Vishwanath Swarup , CEO @BSV_Global at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

The issue really happens when there is unpredictability in the pricing policy or when there are a few areas in the fringe, because how do you really price innovative medicines?-Mr. Rajaram Narayanan , MD @IndiaSanofi at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"India can be a stellar example in really achieving & realizing aspirations of universal health cover through the coming together of political will, private sector capability, capacity & ingenuity & public demand for accountable care" Mr. kaivaan Movdawalla @EY_India @ #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"Access to essential medicines or technologies are a part of the fulfilment of their right to health. And it has been recognized in the constitution of India & it is a mandatory privilege"-Dr. S. Eswara Reddy, Joint Drugs Controller GOI at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"There is no doubt that India requires universal healthcare & private healthcare cannot be a substitute to public healthcare. Private can only complement & fill in few gaps"-Mr. Ashutosh Raghuvanshi, MD & CEO @fortis_hospital at #IMD & #IP

[India Pharma 2021 @Ind_Pharma]

"India is in a unique position for differential pricing because we have a large public sector that caters to volumes & can command lower prices & at the same time we have a population that can pay higher for private institutions"-
LI Gen Nardeep Naithani, Director @afmc_pune